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The growing global burden of non communicable diseases (NCDs) is now killing 36 million people each year and
needs urgent and comprehensive action. This article provides an overview of key critical issues that need to be
resolved to ensure that recent political commitments are translated into practical action. These include: (i)
categorizing and prioritizing NCDs in order to inform donor funding commitments and priorities for intervention;
(ii) finding the right balance between the relative importance of treatment and prevention to ensure that responses
cover those at risk, and those who are already sick; (iii) defining the appropriate health systems response to address
the needs of patients with diseases characterized by long duration and often slow progression; (iv) research needs,
in particular translational research in the delivery of care; and (v) sustained funding to support the global NCD
response.
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The growing global non-communicable disease (NCD)
crisis is now killing 36 million people each year and
needs urgent and comprehensive action [1]. Rapidly in-
creasing globalization is accompanied by urbanization,
population growth and ageing, and trends towards un-
healthy lifestyles, including unhealthy diets, physical in-
activity, obesity, and immoderate alcohol and tobacco
use. Chronic NCDs are defined by the World Health
Organization (WHO) as cardiovascular diseases (CVD),
diabetes, chronic respiratory diseases, and cancer. This
grouping of chronic NCDs reflects their association with
common shared risk factors: harmful use of alcohol,
tobacco use, physical inactivity and unhealthy diets [2].
Non-communicable diseases in low-income and middle-
income countries currently account for 80% of the
worldwide NCD mortality caused by CVD, cancers, dia-
betes and chronic lung diseases [3].
Attention to NCDs is increasing for several reasons.
First country-level data show that these conditions are
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reproduction in any medium, provided the orrange of low- and middle-income countries [3]. Second,
these data support estimated disease projections of a
growing burden of morbidity and mortality associated
with chronic NCDs. Third, NCDs have a huge negative
economic impact [4] and represent a significant impedi-
ment to human development [5]. Fourth, recent progress
in mobilising funds and improving the response to infec-
tious diseases (especially HIV/AIDS, tuberculosis and
malaria) has stimulated a broader global health outlook.
These factors culminated in a United Nations (UN)
High-Level Meeting on NCDs in New York in Septem-
ber 2011 [6].
A worldwide goal for the prevention and control of
NCDs has been proposed to complement existing MDG
targets for communicable disease control, with the ac-
companying target of an additional 2% per year reduc-
tion in death rates attributable to the main chronic
diseases (heart disease, stroke, cancer, diabetes, and
chronic respiratory diseases) [7]. Achieving this goal will
require comprehensive action covering the range of dis-
eases and risk factors through a two-pronged approach:
implementation of the multisectoral policies aimed at
decreasing population-level risks for NCDs, and effective
and affordable delivery of health sector interventions for
patients with NCDs.
Feasible and cost-effective health sector interventions
exist for the priority chronic NCDs. For example,Ltd. This is an Open Access article distributed under the terms of the Creative
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people with a high risk of ulcers have been ranked as
priority low-cost interventions for diabetes control [8].
For the management of individuals with chronic vascular
disease cost-effective interventions include treatments
with low cost generic drugs, lifestyle and behavioural
changes, and rehabilitative measures [9]. The potential
impact of scaling up evidence-based health sector inter-
ventions for the prevention of NCDs in low-income and
middle-income countries is considerable. As an example,
scaling up a multidrug regimen (the ‘polypill’, i.e. a statin,
aspirin, and two antihypertensive drugs) for the preven-
tion of CVD in high-risk individuals could avert 18
million deaths over a 10-year period, at an average yearly
cost per head of $1.08 [10]. The identification of simple,
low-cost interventions is all the more important for
developing countries, which generally have under-
resourced health-systems, particularly in rural areas.
This paper will address a number of key policy issues
that will need to be addressed to enable an effective re-
sponse to NCDs in low- and middle-income countries.
Key policy issues
Categorizing and prioritizing NCDs
Given the enormously broad range of diseases which are
non-communicable it is necessary to group certain dis-
eases for certain purposes. Whichever grouping of
chronic NCDs is used for a particular purpose, it is im-
portant to specify the criteria for the inclusion of the
particular NCDs in that grouping.
The definition of the priority NCDs – CVD, diabetes,
chronic respiratory diseases, and cancer - by WHO is
based on their shared risk factors and therefore a com-
mon approach to their prevention. Within the individual
disease categories there are also groupings of diseases
linked by shared risk factors and therefore amenable to
similar approaches for their control. For example, within
the group of CVDs, the primary and secondary preven-
tion of ischaemic heart disease and ischaemic cerebro-
vascular disease (e.g. ischaemic stroke and transient
ischaemic attacks) rely on similar measures, including a
healthy diet, use of aspirin and statins, smoking cessa-
tion, and hypertension control. The focus of WHO
efforts is to try to ensure that the priority NCDs are ur-
gently accorded greater attention in the health and de-
velopment policies of poor nations and on global aid
agendas. Recent efforts include the launch of the new
global initiative in July 2009 [11] and the WHO contri-
bution to the UN high-level meeting on NCDs in Sep-
tember 2011 [12].
As a group of chronic NCDs, CVD, diabetes, and
chronic respiratory diseases share the following specific
characteristics: 1) they can be detected using simple tests
available (or potentially readily available) in primary caresettings in low-income countries: hypertension (sphyg-
momanometer), chronic airflow obstruction (peak
expiratory flow meter), diabetes (urine or blood glucose)
and obesity (weight and height); 2) they can be readily
managed in typical primary care settings in middle- and
low-income countries; 3) the benefits of prevention and
care extend to related conditions of public health im-
portance, e.g. chronic kidney disease (often caused by
hypertension or diabetes). These shared characteristics
are the basis for inclusion of these diseases in a pro-
posed framework for NCD primary care in developing
countries [13]. The approach to each NCD has its own
specific set of challenges, and cancer in particular repre-
sents a special case. Since capacity for managing people
with cancer in many developing countries, especially in
Africa, is very limited and invariably centralised [14] the
health-care system response to people with cancer
involves in some ways a greater challenge than the
response to people with CVD, diabetes, and chronic
respiratory diseases.
The implications of a particular disease being included
on a list for an international agenda are crucial. For ex-
ample, the grouping of HIV, tuberculosis and malaria as
“priority diseases of poverty” had immense implications
for funding, as these specific diseases became the benefi-
ciaries of increased international funding through the es-
tablishment of the Global Fund to Fight AIDS,
Tuberculosis and Malaria.
Depending on the purpose of grouping a set of chronic
NCDs in a particular category, there may be leeway for a
flexible approach to grouping. For example, the initial
grouping of NCDs in the framework for a structured ap-
proach to the prevention and management of chronic
NCDs in primary care can potentially be extended to in-
clude other chronic NCDs such as chronic kidney dis-
ease, chronic liver disease and chronic organic brain
syndromes (e.g. the dementias). One area of recent con-
tention has been the relegation of psychiatric conditions
to a second ranking in the list. For example, at the First
Global Ministerial Conference on NCDs and Healthy
Lifestyles held in Moscow from 28–29 April 2011, men-
tal disorders were included in the declaration under the
“other NCD” category: “In addition, other NCDs such as
mental disorders also significantly contribute to the glo-
bal disease burden” [15]. This is in contrast to disease
projections which put mental health disorders at the top
of the global disease burden league table by 2030.
Relative importance of prevention and care
There is debate about the relative importance of preven-
tion and care regarding the common priority chronic
NCDs as defined by WHO. In the run-up to the UN
high-level meeting the focus of discussions in leading
medical journals on priority actions within the health
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prevention of NCDs – policies which lie beyond the
health sector and mainly require government action,
such as tobacco and alcohol control, ensuring environ-
mental safety, and promotion of agricultural and food
industry reforms [16,17]. Multisectoral actions for pre-
vention are necessary to reduce the future disease bur-
den, but must be accompanied by health sector actions
for care, considering that it is the current disease burden
that is essentially being used to justify the investments
mainly aimed at prevention. One of the lessons learned
from previous pioneering UN summits on HIV is the
importance of agreeing on priority actions for both pre-
vention and care, which may be mutually reinforcing
[18]. For example, meeting the care needs of people with
NCDs may enhance the impact of prevention policies,
since people are more likely to test for a disease for
which there is a good prospect of effective treatment.
Conversely, in populations where up to 30% of adults
may have a chronic NCD, prevention policies that sup-
port healthier diets, more physical activity, less smoking
and less harmful use of alcohol create an environment
which facilitates the adoption of these lifestyle measures
which are a key part of the management of conditions
such as diabetes, hyptertension, CVD and chronic re-
spiratory disease.
In the present era of global economic crisis and fiscal
restraint, governments are exploring ways of decreasing
expenditures on social sectors, including health [19].
Arguments for prevention based on economic benefits
are likely to find a more sympathetic ear among govern-
ments and international funders than arguments for
increased spending on care. Chronic NCDs by definition
are not curable and so patients require lifelong care. It
may be difficult to convince funders and some elements
of the healthcare professions of the benefits of investing
in detection and treatment of chronic NCDs when some
are asymptomatic and the benefit for individuals of de-
tection and treatment is expressed as a likelihood rather
than certainty, e.g. hypertension. However, there are
enough data showing that the impact of NCDs such as
hypertension, CVD and diabetes is similar in different
parts of the world, and the benefits of investment in care
of people with NCDs are just as likely to apply in devel-
oping countries as in developed countries. Any popula-
tion differences in disease manifestations and responses
to treatment need to be taken into consideration in
planning and implementing health care delivery rather
than used as a potential argument against NCD care de-
livery in certain populations. This is the case in devel-
oped countries, where health care delivery is adapted to
meet the specific needs of people whose origin in devel-
oping countries is associated with population-specific
differences in NCD progression and presentation, e.g.increased risk of type 2 diabetes and subsequent CVD in
people of south Asian origin.
There may be some unwillingness among the inter-
national health community to take on the enormous task
of providing quality lifelong care for people with NCDs
at a time when a sense of “combat fatigue” is becoming
apparent in relation to the effort to provide lifelong
treatment for people with HIV infection. This effort is
slackening off even before the task is half completed
[20]. It may be the case that the health sector experts’
emphasis on priorities for action outside the health sec-
tor represents an unspoken unwillingness to embrace
the challenge of large scale action in the health sector
for people with NCDs. Just as pioneering projects by
Médecins sans Frontières (MSF) and others changed the
mindset that “HIV treatment in developing countries is
too difficult” [21], similar pioneering projects may well
be needed to show that the mindset that “NCD treat-
ment on a massive scale in developing countries is too
difficult” is untenable.
As the global community gears up towards actions
and investments aimed at limiting the number of future
potential NCD patients, the voice of health advocates
representing the needs of people with NCDs for quality
care today and tomorrow needs to find its place. A bal-
ance must be found between the upstream, multisectoral
policies for NCD prevention aimed at the benefit of fu-
ture generations, and the downstream, health sector
interventions for ensuring that people with NCDs obtain
quality care.
The health system response to NCDs in developing
countries
The inverse care law applies to the global problem of
NCDs: with 80% of global NCD deaths occurring in low
and middle-income countries, those most in need of
care have least access. The need to improve the health
system response in developing countries is greatest in
sub-Saharan Africa, which faces the greatest predicted
increase in NCD deaths [11] and has the least resources
for an effective response to the double burden of com-
municable diseases and NCDs. Health systems in devel-
oping countries have often been orientated towards
tackling communicable disease, and the approach to
NCDs is often unstructured, lacks systematic follow-up
and monitoring of chronic clinical care, and provides lit-
tle information about morbidity or mortality, which is
crucial for effective health planning [22]. There is there-
fore broad agreement that “Health systems need to be
further strengthened to deliver an effective, realistic and
affordable package of interventions and services for
people with NCDs” [2]. The importance of overall
strengthening of health systems is as relevant for an ef-
fective response to NCDs as to chronic communicable
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tems also need to be reoriented to managing people with
chronic conditions. The structure of these health sys-
tems generally reflects a model of health care response
to acute episodes of illness. The increasing burden of
chronic disease in low-income countries poses a chal-
lenge in reorienting health systems so that they can ad-
dress the needs of patients with diseases characterised
by long duration and often slow progression [24]. The
progress made in developing successful ways of man-
aging chronic infectious diseases, including community-
based support, such as tuberculosis and HIV infection is
proof of principle that a reoriented health-care system
response to chronic diseases is possible.
Role of primary care
The scale of the burden of NCDs and the cost implica-
tions point towards the importance of a response to NCDs
centred on primary care rather than hospitals at secondary
or tertiary level [24]. The importance of a strong health
system led by primary care is receiving renewed attention
[25]. Primary-care providers include those in the govern-
ment services (Ministry of Health, social-security, prisons,
military) and nongovernment services (nongovernmental
organizations and private practitioners). In practice, sec-
ondary and tertiary care institutions often also provide pri-
mary care in addition to playing a referral role. Primary-
care delivery in sub-Saharan Africa has shortcomings: it
may be impoverishing, fragmented, unsafe or misdirected
[26]. However, a key strength of primary care is that it is
the main entry point into health services for most people.
It has played a successful role in the delivery of prevention
and care interventions for communicable diseases such as
tuberculosis, HIV and malaria. Building on this success,
primary care could potentially play a key role in the deliv-
ery of prevention and care interventions [27]. Investing in
improved primary care has the potential to overcome
some of the problems identified with the current health
system approach to NCDs [28]. The practical policy
proposals to improve the primary care response to the
problem of NCDs in developing countries undergoing
health transition include the following: (i) improving data
on communicable and non-communicable diseases; (ii)
implementing a structured approach to the improved de-
livery of primary care; (iii) putting the spotlight on quality
of clinical care; (iv) aligning the response to health transi-
tion with health system strengthening; and (v) capitalizing
on a favourable global policy environment [28].
The need for a public health approach to care of people
with NCDs
At present the health system approach to NCDs in
developing countries is generally on an individual basis,
i.e. a patient consults a care provider who delivers healthinterventions. This individual approach to care is in con-
trast to a public health approach in which a program-
matic structure enables systematic follow-up, monitoring
of the quality of care, and routine collection and report-
ing of information about patient outcomes, morbidity
and mortality (information which is crucial for effective
health planning). A focus on quality care is key in bridg-
ing clinical care and public health [29].
It is useful to review briefly the development of the
public health approach to provision of ART for people
with HIV infection to provide a concrete example of a
public health approach to care in action. Based on ex-
tensive evidence that ART can substantially extend the
life of people with HIV infection, guidelines for indus-
trialised countries covered individual patient manage-
ment delivered by specialist doctors prescribing from a
wide range of ARVs supported by routine high-
technology laboratory monitoring. Such an approach is
not feasible in resource-limited settings where doctors
are scarce, laboratory infrastructure is inadequate, and
the procurement and supply-chain management is fra-
gile. The difficulty in translating the guidelines from
developed to developing nations caused concerns over
whether ART scale-up in poor countries was feasible, let
alone affordable or cost-effective.
Drawing on the experience of the internationally
recommended tuberculosis control strategy [30], a
public-health approach to providing ART was developed
[31]. This approach took into account country require-
ments, the realities of weak health systems, and the
experiences of pioneering ART programmes such as
those of Médecins sans Frontières. Standardisation of
diagnosis and treatment and simplification of regimens
support efficient implementation [32]. A structured pub-
lic health approach promotes implementation of
evidence-based programmes and equity (setting stan-
dards for treatment that should be accessible by all in
need). The move from an individual-based approach to a
population-based one was recognised as the only way to
make ART rapidly accessible to the millions in need and
was a key conceptual shift [33]. The public health ap-
proach to the delivery of individual health interventions
has enabled substantial, if still incomplete, progress in
rolling out interventions for the diagnosis and treatment
of tuberculosis [34] and HIV infection [35].
Although a public health approach to the delivery of
individual health interventions is crucial to providing
wide access to quality care, these lessons have not so far
been applied for the benefit of people with NCDs. For
example, the WHO global NCD status report describes
the NCD burden and inadequacies of the current health
system response but gives weak guidance about how
interventions can be delivered [2]. The report dedicates
a chapter to “Individual Health Interventions” without
Maher et al. Globalization and Health 2012, 8:14 Page 5 of 8
http://www.globalizationandhealth.com/content/8/1/14addressing need for a public health approach to the de-
livery of “individual health interventions” [2].
The strategy for addressing the needs of people with
NCDs in a public health approach has three key ele-
ments: identifying and addressing modifiable risk factors;
screening for common NCDs; and diagnosing, treating,
following up and, when necessary, referring patients with
common NCDs using standard protocols [13]. The pack-
age of interventions for quality care comprises political
commitment, case-finding among people attending pri-
mary care services, standardised diagnostic and treat-
ment protocols, regular drug supply, and systematic
monitoring and evaluation. Given the enduring crisis in
human resources, task shifting, community engagement,
and the enrolment of expert patients are all likely to be
critical - a lesson learned from the HIV experience [36].
There is an urgent need to evaluate such an approach
in the field and if found successful to extend it on a wide
scale, analagous to massive scale-up of the international
strategy for tuberculosis control and of the public health
approach to ART access [37]. A focus on providing qual-
ity care can provide a link between clinical and public
health approaches to NCDs as shown for HIV infection
[29]. Sub-optimal care for many people with chronic dis-
ease is a problem worldwide, e.g. hypertension and dia-
betes are poorly controlled in a high proportion of
patients even in developed countries. The lessons
learned from using a structured public health approach
to improve on a large scale the quality of care for people
with chronic diseases in developing countries may also
be relevant to countries in the developed world, espe-
cially those where the poor and disadvantaged have lim-
ited access to ongoing healthcare provision (e.g. USA).
One key lesson from both HIV care in developing
countries and NCD care in developed countries is the
need for policies and approaches that make care more
patient centered, including shared decision-making, and
promote patient activation and empowerment. These
important lessons should be integral to NCD care in
resource-limited settings where access to health centres
and providers is limited, and the potential contribution
of patients as co-providers of care is all the more
important.
Interaction between communicable diseases and NCDs
An increasing disease burden arises from interactions
between communicable diseases and NCDs [38], e.g. be-
tween tuberculosis and poor nutritional status and
tobacco use, diabetes and infection (with diabetes pre-
disposing to infections which often exacerbate hypergly-
caemia). Common NCDs arising from the current high
burden of chronic communicable diseases in Africa in-
clude cervical cancer linked to human papilloma virus
infection and hepatoma linked to hepatitis B virusinfection. The burden of chronic NCDs is likely to be
further uncovered as scaled-up programmes of antiretro-
viral treatment of HIV-infected people reduce mortality
but increase morbidity related to chronic HIV infection
and treatment. Increasing numbers of people in Africa
are therefore at risk of possible metabolic side effects
resulting from life-long antiretroviral treatment [35], e.g.
diabetes, lipodystrophy and dyslipidaemia. These over-
laps between communicable diseases and NCDs present
opportunities for synergistic care within the context of
strengthened health systems [38].
At least 2 million cancer cases per year (18% of the
global cancer burden) are attributable to a few specific
chronic infections, and this fraction is substantially lar-
ger in low-income countries [2]. The principal infectious
agents are human papillomavirus (cervical cancer), hepa-
titis B virus and hepatitis C virus (liver cancer) and Heli-
cobacter pylori (gastric cancer). These infections are
largely preventable through vaccinations and measures
to avoid transmission, or are treatable. For example,
transmission of hepatitis C virus has been largely
stopped among high-income populations, but remains a
problem in many low-resource countries [2].
Ensuring access to affordable diagnostics and drugs
An essential lesson from the scale-up of HIV treatment
is that a concerted international effort is required to
bring down the cost of essential diagnostics and drugs,
since many essential drugs for NCDs are unaffordable
and consequently unavailable in many resource-limited
settings [39]. In response to the often limited access to
anti-asthma drugs provided at a relatively high cost [40]
the Asthma Drug Facility was established to promote
the supply of drugs for asthma and may be further
extended to drugs for other NCDs [41]. The model drug
supply system for the Asthma Drug Facility is the Global
Drug Facility for anti-TB drugs [42]. In the case of anti-
retroviral drugs for HIV/AIDS, the most important
driver of affordable treatment was the introduction of
generic competition that drove down the global cost of
treatment by over 90% within just a few years [43]. Thus
different approaches are available to policy makers to
drive down drug prices and increase access, and these
should be considered early in the NCD response.
Ensuring reliable drug supply is a critical area and
again there are lessons from HIV. Considerable efforts
have been made to reinforce drug forecasting, support
supply chain management, and rational use of antiretro-
virals, supported by organizations such as The Clinton
Health Access Initiative and UNITAID. These lessons
too should be applied in the scale up of NCD treatment
access.
Finally, access to essential diagnostics should not be
neglected. Viral load has been recognized as an
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ment of HIV yet a decade into the scale up response,
viral load remains too complex and costly for the major-
ity of high HIV-burden countries [44].
Priority research needs
Since there are enough data to show that the impact of
NCDs such as hypertension and diabetes is essentially
similar in different populations around the world, the
priority research need is for operational research in the
delivery of care [45]. So what should be delivered is, to a
considerable degree, well known, but how to deliver it
effectively in low-resource settings is much less well
known. Basic epidemiology provides needs assessment
in establishing the population burden of NCDs, and then
highly pragmatic translational intervention studies en-
able validation and adaptation of the package of available
interventions which are known to be cost-effective and
the public health framework for delivering it. Where
there is incomplete information on NCD epidemiology,
presentation, progression and response to treatment, re-
search is needed to fill the gaps [37]. For example, the
sorts of large prospective studies on epidemiology, prog-
nosis and treatment outcome of hypertension that have
been conducted in developed countries need to be con-
ducted in developing countries. Studies of prognosis can
be conducted in the context of learning about how to
deliver care.
A crucial issue is that limited research is currently
being conducted on chronic NCDs in developing coun-
tries, especially in sub-Saharan Africa, and resources for
such research are severely limited. Overcoming this
problem requires both increased investment and more
efficient use of resources. The main international re-
search funders have shown some signs of increased
interest in funding research on NCDs, but with a focus
on the large emerging economies such as China and
India [46]. One way of using research resources more ef-
ficiently is to identify existing research infrastructures
established for other purposes and use them for research
on NCDs [47]. This avoids incurring the costs of estab-
lishing an entirely new research infrastructure specific-
ally for NCDs in countries with severely constrained
resources. An example of the success of this approach is
the use of a research infrastructure in rural Uganda ini-
tially established for survey of HIV infection as a plat-
form for survey of hypertension and other chronic
NCDs provides [48,49].
Arguments for investment in disease prevention and
management can be based on promoting health as a
human right and as a contributor to poverty reduction
and economic stability. The economic case was made
successfully in the past for tuberculosis [50] and more
recently for HIV [51], and now needs to be developedfor investment in a two-pronged approach to the global
problem of NCDs: the upstream multisectoral actions
for prevention, and the complementary downstream
health sector actions for care. Detailed analyses have
been done on funding for other priority global health
problems such as HIV, tuberculosis and malaria. Re-
search is needed to track the financing of delivery of
health care also for people with NCDs, involving exter-
nal donor funding and domestic funding by national
governments. Crucial questions include the sources, ex-
tent and distribution of international funding for NCDs.Global funding
Despite increasing recognition in some quarters of the
double burden in developing countries of chronic com-
municable diseases and chronic NCDs [52], health fun-
ders have not yet mobilized the substantial investment
required to respond to the challenge of hypertension
and other chronic NCDs globally, including in Africa
[53]. Recent progress in mobilizing funds and improving
the response to infectious diseases (especially HIV/AIDS,
tuberculosis and malaria) now enables a shift to a
broader global health outlook, for example, there is
growing discussion about how the Global Fund To Fight
Aids, Tuberculosis And Malaria can drive broad
improvements in general health systems, which should
also include a focus on NCDs [54]. New alliances, such
as the Global Alliance for Chronic Diseases, may provide
an opportunity for concerted action to put the evidence
base for treatment and control of NCDs in developing
countries on a firm footing. The challenge is to ensure
that funding streams for chronic diseases are sustained
over time. The sustainability of the current, largely ex-
ternally funded approach to provide universal access to
ART is currently under threat due to faltering donor
commitments in the enduring global economic crisis.
This should provide sober reflection to the enthusiasm
around current political commitments to do more for
NCDs: if these commitments are serious, funding must
follow, and it must be sustained.Conclusion
The recent political recognition of the importance of the
global burden of non-communicable diseases is wel-
come, but it remains to be seen how political commit-
ments will translate into practical action, particularly in
resource-limited settings where the challenges of provid-
ing adequate care and treatment are significant. Much
can be learnt from the last decades’ struggle to improve
access to HIV treatment and care [55]. In particular, the
need to balance treatment and prevention, rather than
pit one against the other, needs to be addressed from
the outset.
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